|
 
- 现金
- 9378 元
- 精华
- 18
- 帖子
- 6849
- 注册时间
- 2002-12-5
- 最后登录
- 2003-9-5
|
1楼
发表于 2003-9-4 07:58
DAPD and L-FMAU are nucleoside analog drugs that show potent anti-HBV activity in the laboratory. They also are effective against various HBV strains resistant to Epivir-HBV (lamivudine). DAPD also has anti-HIV activity, while L-FMAU does not. Both agents will proceed to clinical trials.
The report was presented by Ruth Chin, MD, from the Victorian Infectious Disease Laboratory in North Melbourne, Australia. The drugs are being developed by Triangle Pharmaceuticals.
11/10/99
References
Chin R and others. Two novel antiviral agents, DAPD and L-FMAU, which are active against wild type and lamivudine-resistant HBV. Abstract and oral presentation 1041 at the 50th Annual Meeting of the American Association for the Study of Liver Diseases. Dallas, Texas; November 5-9, 1999. Hepatology 30(4) Supp2, 421A
|
|
